{"id":19406,"date":"2022-10-24T12:59:52","date_gmt":"2022-10-24T07:29:52","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19406"},"modified":"2022-11-14T09:54:13","modified_gmt":"2022-11-14T04:24:13","slug":"non-opioid-analgesics-for-chronic-pain-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment","title":{"rendered":"Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients"},"content":{"rendered":"\n<p>Chronic pain is the leading cause of adult disability in the United States. Approximately <strong>50 million<\/strong> Americans are currently suffering from chronic pain. The most common sources of chronic pain are lower back problems, arthritis, cancer, RSDS, repetitive stress injuries, shingles, headaches, and fibromyalgia. Others include diabetic neuropathy, phantom limb sensation, and other neurological conditions. Sports injuries are among the most common causes of chronic pain in people in their twenties. Chronic pain costs society more than <strong>USD 100 billion<\/strong> each year.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>As per the latest <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-epidemiology-forecast\"><strong>Chronic Pain Epidemiology Forecast<\/strong><\/a><strong> report published by DelveInsight, chronic pain affected around 53 million people in the US, 80 million people in the EU5, and another 41 million in Japan in 2021.<\/strong><\/p><\/blockquote>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-83f269b1-ed10-4570-b47f-07ea94cd1660\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.2.1<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-qa1zgg8-800-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-qa1zgg8-804-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-qa1zgg8-805-\"><rect fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 215.5 71 L 215.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 357.5 71 L 357.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 498.5 71 L 498.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 74.5 71 L 74.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 305.5 L 499 305.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 246.5 L 499 246.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 188.5 L 499 188.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 129.5 L 499 129.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 70.5 L 499 70.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"292\" width=\"424\" x=\"75\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.488866806030273 217)\" x=\"26.488866806030273\" y=\"217\">prevalent cases (in million)<\/text><path class=\"highcharts-axis-line\" d=\"M 75 71 L 75 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-qa1zgg8-804-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><rect aria-label=\"US, 53. Prevalent cases (in million).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"155\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"68\" x=\"36.5\" y=\"137.5\"><\/rect><rect aria-label=\"EU5, 80. Prevalent cases (in million).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"234\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"68\" x=\"177.5\" y=\"58.5\"><\/rect><rect aria-label=\"Japan, 41. Prevalent cases (in million).\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"120\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"68\" x=\"318.5\" y=\"172.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Chronic Pain Epidemiological Insights (2021)<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"52\">Prevalent Cases of Chronic Pain in the 7MM<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(75,71) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(58,114)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">53<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>53<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(199,35)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">80<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>80<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(340,149)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">41<tspan dy=\"0\" x=\"5\">\u200b<\/tspan><\/tspan>41<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"145.66666666666333\" y=\"382\">US<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"287.0000000000033\" y=\"382\">EU5<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"428.3333333333333\" y=\"382\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"309\">20<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"250\">40<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"192\">60<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"133\">80<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"75\">100<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Chronic Pain - Epidemiology Forecast - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Chronic Pain &#8211; Epidemiology Forecast &#8211; 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-qa1zgg8-805-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Chronic Pain Epidemiological Insights (2021)\"},\"subtitle\":{\"text\":\"Prevalent Cases of Chronic Pain in the 7MM\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Prevalent cases (in million)\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Prevalent cases (in million)\\\"\\n\\\"US\\\";53\\n\\\"EU5\\\";80\\n\\\"Japan\\\";41\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"prevalent cases (in million)\"}}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Chronic Pain - Epidemiology Forecast - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-epidemiology-forecast\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-83f269b1-ed10-4570-b47f-07ea94cd1660\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>There are numerous pharmacological, adjunctive, non-pharmacological, and interventional treatments available for chronic, severe, and persistent pain. Non-opioid analgesics on this list include <strong>nonsteroidal anti-inflammatories (NSAIDs), acetaminophen, and aspirin<\/strong>. <strong>Tramadol, opioids, and antiepileptic drugs (gabapentin or pregabalin)<\/strong> can all be helpful. Furthermore, antidepressants such as <strong>tricyclic antidepressants and SNRIs, topical analgesics, muscle relaxants, N-methyl-d-aspartate (NMDA) receptor antagonists, and alpha 2 adrenergic agonists<\/strong> are possible pharmacological chronic pain therapies.<\/p>\n\n\n\n<p>Non-pharmacologic chronic pain treatments can include exercise, physical therapy, counseling, electrical stimulation, biofeedback, acupuncture, hypnosis, chiropractic medicine, and other treatments. There are several approved drugs for chronic pain treatment due to different indications, including<strong> Emgality (galcanezumab-gnlm), Aimovig (Eptinezumab), Tarlige (Mirogabalin besylate), Aimovig (Erenumab-aooe), and Ajovy (Fremanezumab), Vyepti (Eptinezumab), and Pennsaid gel.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115305\/FDA-approved-Drugs-for-Chronic-Pain.jpg\" alt=\"Chronic Pain drugs\" class=\"wp-image-19419\" width=\"897\" height=\"626\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115305\/FDA-approved-Drugs-for-Chronic-Pain.jpg 897w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115305\/FDA-approved-Drugs-for-Chronic-Pain-300x209.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115305\/FDA-approved-Drugs-for-Chronic-Pain-150x105.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115305\/FDA-approved-Drugs-for-Chronic-Pain-768x536.jpg 768w\" sizes=\"(max-width: 897px) 100vw, 897px\" \/><figcaption><strong>Marketed Drugs for Chronic Pain Management<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Opioids are regarded as the most effective <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-pipeline-insight\">drugs for chronic pain management<\/a> despite controversies. The goal of chronic pain management is to provide symptom relief and improve an individual\u2019s level of functioning in daily activities.&nbsp;<\/p>\n\n\n\n<p>The use of opioids is considered the standard of care in the management of acute severe pain and chronic pain related to advanced medical illness. However, opioids are widely feared compounds and are associated with abuse, addiction, and the dire consequences of diversion. There are some unmet needs in the chronic pain treatment market. There are various challenges in identifying biomarkers for chronic pain treatment. Also, the mechanism-based chronic pain diagnosis has not been feasible, as its pathophysiological components are not elucidated yet. Therefore, the current chronic pain diagnosis is based solely on clinical signs and symptoms. Nevertheless, some developmental initiatives have recently been taken toward managing chronic pain. Several key pharmaceutical players have taken to the initiative to meet the unmet needs of the present situation of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-market\">chronic pain treatment market<\/a>. Some key players are in the late and mid-clinical development stages with their leading drug candidates for chronic pain treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-musings-on-the-chronic-pain-treatment\"><strong>Musings on the chronic pain treatment&nbsp;<\/strong><\/h2>\n\n\n\n<p>It is not new that the <a href=\"https:\/\/www.delveinsight.com\/blog\/chronic-pain-pipeline\">prevalence of chronic pain<\/a> is high in cancer patients; however, chronic pain is also reported in non-cancer patients suffering from various conditions. It has been discovered that a large percentage of chronic pain patients are suffering from pain caused by osteoarthritis. It is a crippling disease that causes excruciatingly painful joints due to cartilage damage between the joints.<\/p>\n\n\n\n<p>To bridge the treatment gaps in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoarthritis-market\">osteoarthritis treatment market<\/a>, <strong>Paradigm Biopharmaceuticals <\/strong>is developing <strong>ZILOSUL. <\/strong>Pentosan polysulfate sodium (PPS) is a semi-synthetic drug derived from European beech tree wood chips. PPS activity is notable for its anti-inflammatory and tissue regenerative properties, as well as mild anti-thrombotic activity.<\/p>\n\n\n\n<p>In May 2022, <strong>Paradigm <\/strong>announced that the first subjects in the<strong> PARA OA 002 pivotal Phase III clinical trial<\/strong> evaluating injectable PPS\/ZILOSUL for the treatment of pain associated with knee osteoarthritis had been randomized and dosed in the United States (kOA) Moreover, the FDA granted <strong>Fast Track Designation<\/strong> for Paradigm Biopharmaceuticals Ltd.\u2019s Phase III program investigating PPS for osteoarthritis treatment in April 2022.<\/p>\n\n\n\n<p>Similarly, <strong>Noven Pharmaceuticals <\/strong>is also developing a drug to improve the osteoarthritis treatment space. <strong>HP-5000<\/strong> is a transdermal investigational formulation created with <strong>Hisamitsu\u2019s TDDS (Transdermal Drug Delivery System)<\/strong> technology. As one of the transdermal formulation attributes, the investigational product is expected to be a <a href=\"https:\/\/www.delveinsight.com\/report-store\/knee-osteoarthritis-market\">new treatment option for knee osteoarthritis<\/a>, demonstrating efficacy and safety by achieving higher drug delivery to the affected area. The drug is currently in Phase III testing.<\/p>\n\n\n\n<p>Apart from these companies, several other giants such as <strong>AbbVie, Tonix Pharmaceuticals, Pfizer, Centrexion Therapeutics, Anika Therapeutics, Vertanical GmbH, Braeburn Pharmaceuticals, Gr\u00fcnenthal GmbH, Regeneron, Teva Pharmaceuticals, Biogen, <\/strong>and others are also investigating their respective candidates in various chronic pain clinical trials for treatment and management in the 7MM.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-pipeline-insight\">chronic pain pipeline<\/a> looks promising with the emerging therapies including <strong>QULIPTA, TNX-102, reboxetine, CNTX-4975, CINGAL, dronabinol, buprenorphine, RTX-GRT7039, fasinumab, BIIB074, <\/strong>and others.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-pipeline-insight\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115430\/Chronic-Pain-Pipeline-Assessment.png\" alt=\"Chronic Pain Pipeline\" class=\"wp-image-19420\" width=\"672\" height=\"471\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115430\/Chronic-Pain-Pipeline-Assessment.png 672w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115430\/Chronic-Pain-Pipeline-Assessment-300x210.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115430\/Chronic-Pain-Pipeline-Assessment-150x105.png 150w\" sizes=\"(max-width: 672px) 100vw, 672px\" \/><\/a><figcaption><strong>Promising Emerging Therapies for Chronic Pain<\/strong><\/figcaption><\/figure>\n\n\n\n<p>There are several other late-stage assets with distinct MoA being developed for treating chronic pain patients and are expected to enter the US, the EU5 (Germany, Italy, France, Spain, and the United Kingdom), and the Japanese chronic pain treatment market in the next few years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The chronic pain treatment market is all set to grow significantly<\/strong><\/h2>\n\n\n\n<p>The development of disease-specific chronic pain therapies will auger well for the chronic pain treatment market landscape, which, in turn, will facilitate significant changes during the forecast period (2019\u20132032). The chronic pain treatment market is expected to grow significantly with improved diagnosis and safe and efficacious chronic pain treatment options.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>As per DelveInsight analysis, the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-market\"><strong>chronic pain market size<\/strong><\/a><strong> was valued at around USD 21 billion in 2021 and is expected to reach USD 32 billion by 2032 at a CAGR of ~4%.<\/strong><\/p><\/blockquote>\n\n\n\n<p>Nevertheless, pricing and reimbursement challenges, along with associated long-term side effects of approved therapies, are two major factors that influence the chronic pain treatment market success of the upcoming therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115808\/Chronic-Pain-market-assessment-1024x256.png\" alt=\"Chronic Pain Market Assessment\" class=\"wp-image-19421\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115808\/Chronic-Pain-market-assessment-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115808\/Chronic-Pain-market-assessment-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115808\/Chronic-Pain-market-assessment-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115808\/Chronic-Pain-market-assessment-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115808\/Chronic-Pain-market-assessment-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115808\/Chronic-Pain-market-assessment-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21115808\/Chronic-Pain-market-assessment.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>FAQs<\/strong><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1666270320398\"><strong class=\"schema-faq-question\"><strong>1. What is chronic pain?<\/strong><\/strong> <p class=\"schema-faq-answer\">Chronic pain is a pain that lasts for more than three months. It can gradually grow and recur intermittently, outlasting the normal recovery process and adversely affecting the person\u2019s well-being. Pain is supposed to cease after damaged tissue recovers until the root cause is treated.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1666270328842\"><strong class=\"schema-faq-question\"><strong>2. What causes chronic pain?<\/strong><\/strong> <p class=\"schema-faq-answer\">The most common sources of chronic pain are lower back problems, arthritis, cancer, RSDS, repetitive stress injuries, shingles, headaches, and fibromyalgia. Others include diabetic neuropathy, phantom limb sensation, and other neurological conditions. Sports injuries are among the most common causes of chronic pain in people in their twenties.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1666270337960\"><strong class=\"schema-faq-question\"><strong>3. How is chronic pain diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Chronic pain is usually not diagnosed until the patient has been in pain regularly for three to six months. A series of tests and procedures, as well as a review of chronic pain symptoms and medical history, are frequently used for chronic pain diagnosis. The doctor will perform tests based on where the pain is located and what is causing it, as well as other chronic pain symptoms.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1666270348675\"><strong class=\"schema-faq-question\"><strong>4. What is the best medication for severe chronic pain?<\/strong><\/strong> <p class=\"schema-faq-answer\">There are several approved drugs for chronic pain treatment due to different indications, including Emgality (galcanezumab-gnlm), Aimovig (Eptinezumab), Tarlige (Mirogabalin besylate), Aimovig (Erenumab-aooe), and Ajovy (Fremanezumab), Vyepti (Eptinezumab), and Pennsaid gel.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1666270359815\"><strong class=\"schema-faq-question\"><strong>5. Which companies are working in the chronic pain treatment market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Leading companies such as AbbVie, Paradigm Biopharmaceuticals, Tonix Pharmaceuticals, Pfizer, Centrexion Therapeutics, Anika Therapeutics, Vertanical GmbH, Braeburn Pharmaceuticals, Gr\u00fcnenthal GmbH, Noven Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Biogen, and others are investigating their respective candidates in various chronic pain clinical trials for treatment and management in the 7MM.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1666270370536\"><strong class=\"schema-faq-question\"><strong>6. How many therapies are in the chronic pain pipeline?<\/strong><\/strong> <p class=\"schema-faq-answer\">The chronic pain pipeline looks promising with the emerging therapies including QULIPTA, ZILOSUL, TNX-102, reboxetine, CNTX-4975, CINGAL, dronabinol, buprenorphine, RTX-GRT7039, HP-5000, fasinumab, BIIB074, and others.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Chronic pain is the leading cause of adult disability in the United States. Approximately 50 million Americans are currently suffering from chronic pain. The most common sources of chronic pain are lower back problems, arthritis, cancer, RSDS, repetitive stress injuries, shingles, headaches, and fibromyalgia. Others include diabetic neuropathy, phantom limb sensation, and other neurological conditions. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":19411,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16908,19853,19849,19852,19854,19850,19851,19280,19284,1661],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-19406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-chronic-pain","tag-chronic-pain-management","tag-chronic-pain-market","tag-chronic-pain-market-size","tag-chronic-pain-patients","tag-chronic-pain-treatment","tag-chronic-pain-treatment-market","tag-knee-osteoarthritis","tag-knee-osteoarthritis-treatment","tag-osteoarthritis","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Role of Non-opioid Analgesics in Chronic Pain Treatment &amp; Management<\/title>\n<meta name=\"description\" content=\"There are several pharmacological options for chronic pain treatment. Non-opioid analgesics include NSAIDs, acetaminophen, and aspirin.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Role of Non-opioid Analgesics in Chronic Pain Treatment &amp; Management\" \/>\n<meta property=\"og:description\" content=\"There are several pharmacological options for chronic pain treatment. Non-opioid analgesics include NSAIDs, acetaminophen, and aspirin.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-24T07:29:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-14T04:24:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21094243\/non-opioid-analgesics-for-chronic-pain-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Role of Non-opioid Analgesics in Chronic Pain Treatment & Management","description":"There are several pharmacological options for chronic pain treatment. Non-opioid analgesics include NSAIDs, acetaminophen, and aspirin.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment","og_locale":"en_US","og_type":"article","og_title":"Role of Non-opioid Analgesics in Chronic Pain Treatment & Management","og_description":"There are several pharmacological options for chronic pain treatment. Non-opioid analgesics include NSAIDs, acetaminophen, and aspirin.","og_url":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-10-24T07:29:52+00:00","article_modified_time":"2022-11-14T04:24:13+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21094243\/non-opioid-analgesics-for-chronic-pain-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment","url":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment","name":"Role of Non-opioid Analgesics in Chronic Pain Treatment & Management","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21094243\/non-opioid-analgesics-for-chronic-pain-treatment.png","datePublished":"2022-10-24T07:29:52+00:00","dateModified":"2022-11-14T04:24:13+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"There are several pharmacological options for chronic pain treatment. Non-opioid analgesics include NSAIDs, acetaminophen, and aspirin.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270320398"},{"@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270328842"},{"@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270337960"},{"@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270348675"},{"@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270359815"},{"@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270370536"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21094243\/non-opioid-analgesics-for-chronic-pain-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21094243\/non-opioid-analgesics-for-chronic-pain-treatment.png","width":772,"height":482,"caption":"non-opioid-analgesics-for-chronic-pain-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270320398","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270320398","name":"1. What is chronic pain?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Chronic pain is a pain that lasts for more than three months. It can gradually grow and recur intermittently, outlasting the normal recovery process and adversely affecting the person\u2019s well-being. Pain is supposed to cease after damaged tissue recovers until the root cause is treated.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270328842","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270328842","name":"2. What causes chronic pain?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The most common sources of chronic pain are lower back problems, arthritis, cancer, RSDS, repetitive stress injuries, shingles, headaches, and fibromyalgia. Others include diabetic neuropathy, phantom limb sensation, and other neurological conditions. Sports injuries are among the most common causes of chronic pain in people in their twenties.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270337960","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270337960","name":"3. How is chronic pain diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Chronic pain is usually not diagnosed until the patient has been in pain regularly for three to six months. A series of tests and procedures, as well as a review of chronic pain symptoms and medical history, are frequently used for chronic pain diagnosis. The doctor will perform tests based on where the pain is located and what is causing it, as well as other chronic pain symptoms.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270348675","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270348675","name":"4. What is the best medication for severe chronic pain?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"There are several approved drugs for chronic pain treatment due to different indications, including Emgality (galcanezumab-gnlm), Aimovig (Eptinezumab), Tarlige (Mirogabalin besylate), Aimovig (Erenumab-aooe), and Ajovy (Fremanezumab), Vyepti (Eptinezumab), and Pennsaid gel.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270359815","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270359815","name":"5. Which companies are working in the chronic pain treatment market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Leading companies such as AbbVie, Paradigm Biopharmaceuticals, Tonix Pharmaceuticals, Pfizer, Centrexion Therapeutics, Anika Therapeutics, Vertanical GmbH, Braeburn Pharmaceuticals, Gr\u00fcnenthal GmbH, Noven Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Biogen, and others are investigating their respective candidates in various chronic pain clinical trials for treatment and management in the 7MM.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270370536","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/non-opioid-analgesics-for-chronic-pain-treatment#faq-question-1666270370536","name":"6. How many therapies are in the chronic pain pipeline?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The chronic pain pipeline looks promising with the emerging therapies including QULIPTA, ZILOSUL, TNX-102, reboxetine, CNTX-4975, CINGAL, dronabinol, buprenorphine, RTX-GRT7039, HP-5000, fasinumab, BIIB074, and others.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/21094243\/non-opioid-analgesics-for-chronic-pain-treatment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic pain<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic pain management<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic pain market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic pain market size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic pain patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic pain treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic pain treatment market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Knee Osteoarthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Knee Osteoarthritis Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Osteoarthritis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Chronic pain<\/span>","<span class=\"advgb-post-tax-term\">chronic pain management<\/span>","<span class=\"advgb-post-tax-term\">chronic pain market<\/span>","<span class=\"advgb-post-tax-term\">chronic pain market size<\/span>","<span class=\"advgb-post-tax-term\">chronic pain patients<\/span>","<span class=\"advgb-post-tax-term\">chronic pain treatment<\/span>","<span class=\"advgb-post-tax-term\">chronic pain treatment market<\/span>","<span class=\"advgb-post-tax-term\">Knee Osteoarthritis<\/span>","<span class=\"advgb-post-tax-term\">Knee Osteoarthritis Treatment<\/span>","<span class=\"advgb-post-tax-term\">Osteoarthritis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Oct 24, 2022","modified":"Updated on Nov 14, 2022"},"absolute_dates_time":{"created":"Posted on Oct 24, 2022 12:59 pm","modified":"Updated on Nov 14, 2022 9:54 am"},"featured_img_caption":"non-opioid-analgesics-for-chronic-pain-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19406"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19406\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/19411"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19406"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19406"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}